At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Tranexamic Acid Reducing Blood Loss During Maxillofacial Trauma Surgery
In Brief
A Phase 2 clinical trial evaluating Tranexamic Acid (TXA) and Normal saline for Hemoglobin Level Measurement and 2 related conditions. Completed, enrolled 60 participants across 1 site.
Detailed Summary
Tranexamic acid (TXA) is an inexpensive, easily used and relatively safe drug. It inhibits plasminogen activation and plasmin thus retards clot disintegration.Therapeutic application of tranexamic acid in trauma for preventing blood loss has been documented since long. Since blood loss causes several serious complications, it is compensated emergently by transfusion of blood or its products. However, transfusion of blood and products always carries a risk of inadvertent transmission of infection, antigen-antibody reactions and additional cost all of which can be prevented if blood loss is reduced. Morbidity associated with the delay in compensating the blood loss could also be prevented by pharmaceutically preventing hemorrhage.
Study Details
Timeline
Interventions
Thirty minutes prior to surgery, the intervention group receive intravenous , single dose of tranexamic acid of 20 mg/kg.
Thirty minutes prior to surgery, the placebo group received single dose of 20 mL of normal saline.